Passage Bio, Inc. (PASG)

1,5000 -0,0800 (-5,06%) Börsenschluss: 04:00PM EDT

Passage Bio, Inc.

One Commerce Square
39th Floor 2005 Market Street
Philadelphia, PA 19103
United States
267 866 0311
https://www.passagebio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 58

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. William Chou M.D.	President, CEO & Director	945,73k	N/A	1974
Mr. Edgar B. Cale Esq., J.D.	General Counsel & Company Secretary	804,69k	N/A	1964
Dr. Mark Forman M.D., Ph.D.	Chief Medical Officer	866,31k	N/A	1964
Dr. James M. Wilson M.D., Ph.D.	Co-Founder & Chief Scientific Advisor	N/A	N/A	1955
Ms. Kathleen Borthwick	Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1977
Mr. Stuart M. Henderson	Senior Vice President of Corporate Development & Investor Relations	N/A	N/A	N/A
Eden Fucci	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Sue Browne Ph.D.	Senior Vice President of Research & Development	N/A	N/A	N/A
Dr. Karl Whitney Ph.D.	Senior Vice President of Global Regulatory Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Passage Bio, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 3, Vorstand: 5, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.